Sign inJoin waitlistJoin the waitlist

Prerna Kumar

Assistant Professor of Clinical Pediatrics · University of Illinois College of Medicine at Peoria

Credentials: · · ·

History

University of Illinois College of Medicine at Peoria
Present

Hematology and Medical Oncology
University of Colorado School of Medicine
2014–2017
Internal Medicine
University of Colorado School of Medicine
2011–2014
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
2007–2011

Research

Pulse-oximetry screening to detect critical congenital heart disease in the neonatal intensive care unit
Pediatric Cardiology · 2014 · 15 citations
Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives
Review · Cureus · 2018 · First of 6 authors · Corresponding · 10 citations
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma
EJNMMI Research · 2024 · Co-first of 12 authors · Corresponding · 5 citations

Katherine Matthay
4 papers
HI
Hari Iyengar
3 papers · 3 as a resident
PK
Praveen Kumar
3 papers
Benjamin Braun
2 papers
BS
Beth Speckhart
2 papers
Brinda Mehta
2 papers
Daphne Haas-Kogan
2 papers
Steven DuBois
2 papers
WG
William Gustafson
2 papers
WW
William Weiss
2 papers
Aditya Ravindra
1 paper
AR
Alexis Reinders
1 paper

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029